drugset / Trial / NCT00538811

Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders

NCT00538811 ↗

Phase 2/3 Completed 40 enrolled Aga Khan University
RandomizedParallel-groupOpen-labelTreatment

Summary

When administered simultaneously, interferon-alpha 2b + interferon-gamma result in dramatic antiviral synergy.Ribavirin has shown to enhance interferon-gamma levels in patients with chronic hepatitis C treated with interferon-alpha. Enhancement of immune responses, especially those related to type-1 T helper cell activity, may contribute to better efficacy in combining ribavirin with IFN-alpha for treatment of chronic hepatitis C. The aim of the present study is to evaluate the efficacy and safety of a triple regimen, a combination treatment with Interferon gamma, Interferon alfa-2b plus Ribavirin in patients who have not previously responded to interferon alpha in combination of ribavirin.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amantadine Unknown 100 mg —
Subject interferon gamma Protein / enzyme biologic 2 iu —
Background Ribavirin Small molecule 800 mg —
Background Ribavirin Small molecule 1200 mg —
Background interferon alfa-2b Protein / enzyme biologic 3 iu —